Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. Co. is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. We show 50 historical shares outstanding datapoints in our RGLS shares outstanding history coverage, used to compute RGLS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RGLS market cap history over the course of time is important for investors
interested in comparing RGLS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RGLS versus a peer is one thing; comparing
RGLS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RGLS can fluctuate over the course of history.
With this page we aim to empower investors researching RGLS by allowing them to research the RGLS market cap history. |
Free RGLS Email Alerts:
Video: The Importance of Market Cap
